M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Recruiting

Conditions: Arthritis
Polymyalgia Rheumatica
Immune Checkpoint Inhibitors

First Posted Date: 2024-10-17

Last Posted Date: 2024-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT06647134

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study

Phase 1

Recruiting

Conditions: Impulse Control Disorder

First Posted Date: 2024-10-15

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06639594

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Recruiting

Conditions: Cytomegalovirus Cell Mediated Immunity
Hematopoietic Cell Transplant

First Posted Date: 2024-10-15

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 105

Registration Number: NCT06639854

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Phase 2

Not yet recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Golidocitinib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2024-10-08

Last Posted Date: 2024-10-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06630091

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

Phase 2

Not yet recruiting

Conditions: Malignant Solid Tumors

Interventions: Drug: Asciminib

First Posted Date: 2024-10-08

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06629584

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

Phase 2

Not yet recruiting

Conditions: Colorectal Cancer

Interventions: Drug: AMB-05X

First Posted Date: 2024-10-01

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT06617858

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

Phase 2

Not yet recruiting

Conditions: Myelofibrosis

Interventions: Drug: Ruxolitinib
Drug: INCB57643

First Posted Date: 2024-09-30

Last Posted Date: 2024-09-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT06619522

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase Ib Study of Rezatapopt in Combination With Azacitidine or Azacitidine and Venetoclax in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Phase 1

Not yet recruiting

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Rezatapopt
Drug: Venetoclax

First Posted Date: 2024-09-27

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT06616636

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Closed Loop Spinal Cord Stimulation for Chemotherapy Induced Peripheral Neuropathy, a Pilot Study.

Not Applicable

Not yet recruiting

Conditions: Peripheral Neuropathy Due to Chemotherapy

Interventions: Device: Spinal cord stimulator implant

First Posted Date: 2024-09-27

Last Posted Date: 2024-09-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT06616649

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

Phase 2

Not yet recruiting

Conditions: Chronic Myelomonocytic Leukemia
Advanced Myeloproliferative Neoplasms
IDH1-mutated Higher-Risk Myelodysplastic Syndromes

Interventions: Drug: Azacitidine (AZA)
Drug: Decitabine
Drug: Olutasidenib
Drug: Cedazuridine

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT06597734

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy